Andy May

Andy is an Entrepreneur In Residence at DCVC Bio. Andy has spent much of his career at early-stage biotechnology companies, building teams and developing technologies from concept to commercial product. He currently works with a number of companies with technology platforms that are targeted towards solving some of the outstanding problems in gene and cell therapy. He was most recently the Chief Technology Officer at Sana Biotechnology, where he led teams focused on targeted cellular delivery, genome engineering, computational biology and genomics. Prior to Sana, Andy was one of the first scientific leaders at the CZ Biohub, where he built a Genome Engineering platform, focusing on the design and engineering of cells and biological devices as diagnostics and therapeutics, DNA repair mechanisms in genome editing, and large-scale single-cell sequencing experiments. Andy was also the Chief Scientific Officer at Caribou Biosciences. He was a co-founder and served on the Board of Directors at Intellia Therapeutics. Earlier in his career, Andy developed commercial products for single-cell sequencing, cell-free DNA sequencing, HLA-typing and structural proteomics at Fluidigm Corporation, and worked in drug discovery teams at Thios Pharmaceuticals and Signature Biosciences.

Andy was a Wellcome Trust International Postdoctoral Fellow in the Department of Structural Biology at Stanford University, having received his D.Phil. in Molecular Biophysics and a B.A. in Chemistry at the University of Oxford. He has published widely in leading scientific journals, and is an inventor on over 100 patents and patent applications.